Ankündigung • Jun 01
Diaceutics PLC, Annual General Meeting, Jun 25, 2026 Diaceutics PLC, Annual General Meeting, Jun 25, 2026. Location: first floor, building two, dataworks, kings hall health and wellbeing park, county antrim bt9 6gw, belfast United Kingdom Reported Earnings • May 26
Full year 2025 earnings released: EPS: UK£0.001 (vs UK£0.02 loss in FY 2024) Full year 2025 results: EPS: UK£0.001 (up from UK£0.02 loss in FY 2024). Revenue: UK£38.4m (up 20% from FY 2024). Net income: UK£97.0k (up UK£1.80m from FY 2024). Profit margin: 0.3% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings. Buy Or Sell Opportunity • Feb 18
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 2.1% to UK£1.60. The fair value is estimated to be UK£2.03, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 54% in 2 years. Earnings are forecast to grow by 96% in the next 2 years. Ankündigung • Jan 28
Diaceutics PLC to Report Fiscal Year 2025 Results on May 27, 2026 Diaceutics PLC announced that they will report fiscal year 2025 results at 8:00 AM, GMT Standard Time on May 27, 2026 Price Target Changed • Jan 23
Price target increased by 10% to UK£2.21 Up from UK£2.00, the current price target is an average from 5 analysts. New target price is 30% above last closing price of UK£1.70. Stock is up 16% over the past year. The company posted a net loss per share of UK£0.02 last year. New Risk • Jan 15
New major risk - Revenue and earnings growth Earnings have declined by 62% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company. Ankündigung • Jan 15
Diaceutics PLC Provides Earnings Guidance for the Year Ended December 31, 2025 and Fiscal Year 2026 Diaceutics PLC provided earnings guidance for the year ended December 31, 2025 and fiscal year 2026. For the year ended December 31, 2025, reported revenues are expected to be £38.5 million (FY 2024: £32.2 million), representing growth of 20% in the year.
For the year 2026, the company expects to deliver 25% revenue growth. Buy Or Sell Opportunity • Sep 30
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 47% to UK£1.66. The fair value is estimated to be UK£1.37, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Meanwhile, the company became loss making. Reported Earnings • Sep 26
First half 2025 earnings: EPS and revenues miss analyst expectations First half 2025 results: UK£0.028 loss per share (improved from UK£0.031 loss in 1H 2024). Revenue: UK£14.6m (up 18% from 1H 2024). Net loss: UK£2.40m (loss narrowed 7.1% from 1H 2024). Revenue missed analyst estimates by 8.4%. Earnings per share (EPS) also missed analyst estimates by 53%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 103 percentage points per year, which is a significant difference in performance. Ankündigung • Aug 05
Diaceutics PLC to Report Q2, 2025 Results on Sep 15, 2025 Diaceutics PLC announced that they will report Q2, 2025 results on Sep 15, 2025 Ankündigung • Jul 31
Diaceutics PLC Appoints Lauren Dewitt as Executive Vice President, Legal, General Counsel, and Group Company Secretary Diaceutics PLC announced the appointment of Lauren DeWitt as Executive Vice President, Legal, General Counsel, and Group Company Secretary. She will be based at the company's U.S. headquarters. Lauren brings extensive legal and leadership experience in the pharmaceutical sector. Most recently, she served as Vice President and Head of General Legal at Sandoz, where she led a team of senior attorneys supporting all facets of the U.S. business, including commercial, regulatory, quality, medical affairs, and compliance. Earlier in her career, Lauren held several key legal roles at both Sandoz and Novartis, including Global Head of Legal BD&L for Novartis Group, where she oversaw complex global transactions and strategic partnerships. She began her legal career as a litigator, representing healthcare and life sciences companies in product liability and general litigation matters. Buy Or Sell Opportunity • Jul 18
Now 26% overvalued after recent price rise Over the last 90 days, the stock has risen 6.2% to UK£1.29. The fair value is estimated to be UK£1.02, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Meanwhile, the company became loss making. Buy Or Sell Opportunity • Jul 02
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 1.7% to UK£1.13. The fair value is estimated to be UK£1.45, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 25% in a year. Earnings are forecast to grow by 100% in the next year. Buy Or Sell Opportunity • Jun 03
Now 26% undervalued after recent price drop Over the last 90 days, the stock has fallen 9.0% to UK£1.27. The fair value is estimated to be UK£1.70, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 25% in a year. Earnings are forecast to grow by 100% in the next year. Ankündigung • May 22
Diaceutics PLC, Annual General Meeting, Jun 18, 2025 Diaceutics PLC, Annual General Meeting, Jun 18, 2025. Location: first floor, building two, dataworks at kings hall health and wellbeing park, county antrim bt9 6gw, belfast United Kingdom New Risk • May 18
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: UK£630k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. This is currently the only risk that has been identified for the company. Recent Insider Transactions • May 18
Founder & Executive Chairman recently sold UK£630k worth of stock On the 13th of May, Peter Keeling sold around 500k shares on-market at roughly UK£1.26 per share. This transaction amounted to 3.2% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Peter's only on-market trade for the last 12 months. Ankündigung • Apr 29
Diaceutics PLC to Report Fiscal Year 2024 Final Results on May 13, 2025 Diaceutics PLC announced that they will report fiscal year 2024 final results at 8:00 AM, GMT Standard Time on May 13, 2025 Major Estimate Revision • Feb 12
Consensus estimates of losses per share improve by 26% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from UK£31.4m to UK£31.8m. EPS estimate increased from -UK£0.016 per share to -UK£0.012 per share. Life Sciences industry in the United Kingdom expected to see average net income growth of 4.1% next year. Consensus price target up from UK£1.93 to UK£1.99. Share price rose 4.5% to UK£1.39 over the past week. Price Target Changed • Jan 29
Price target increased by 10% to UK£1.93 Up from UK£1.75, the current price target is an average from 5 analysts. New target price is 40% above last closing price of UK£1.39. Stock is up 33% over the past year. The company is forecast to post a net loss per share of UK£0.016 next year compared to a net loss per share of UK£0.021 last year. Ankündigung • Jan 28
Diaceutics PLC Announces Remuneration Committee Chair Changes, Effective 1 May 2025 Diaceutics PLC announced that Graham Paterson, Senior Independent Director, will, effective 1 May 2025, step down as Chair of the Remuneration Committee (but will remain a member of the Remuneration Committee) and Cheryl MacDiarmid will become Chair of the Remuneration Committee at that time. Cheryl MacDiarmid joined the Company Board as a Non-Executive Director in October 2024 and is a Non-Executive Director and serves as Remuneration Committee Chair at Allergy Therapeutics PLC. Ankündigung • Oct 15
Diaceutics PLC Announces the Appointment of Sandra Blake as Chief People Officer Diaceutics PLC announced the appointment of Sandra Blake as Chief People Officer. Sandra has over 25 years leadership experience across Human Resources, Marketing & Innovation in the Technology, Engineering, Banking, Insurance, FMCG, Retail and Energy sectors. Sandra has worked with companies including NatWest Group PLC, Tesco PLC, Cadbury PLC and Kraft Foods Inc. Board Change • Oct 02
Less than half of directors are independent Following Founder & Executive Chairman Peter Keeling's arrival on 01 October 2024, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Graham Paterson was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Ankündigung • Oct 01
Diaceutics plc Announces Board Changes Diaceutics PLC announces the following changes to its board of directors. Jordan Clark (Chief Data Officer of Diaceutics) will join the Board as an Executive Director effective 1 October 2024. Cheryl MacDiarmid will join the Board as a Non-Executive Director subject to the completion of usual Nominated Adviser due diligence checks and a further announcement will be made in due course. Having been on the Board since March 2019, Mike Wort is stepping down as a Non-Executive Director effective 1 October 2024. Graham Paterson who is currently a Non-Executive Director of Diaceutics will assume the role of Senior Independent Director effective 1 October, 2024. In addition, further to the 23 July 2024 announcement, Diaceutics confirms that Deborah Davis has stepped down from the Board with effect from 1 October 2024 and Peter Keeling has succeeded Deborah as Non-Executive Chair. Cheryl MacDiarmid has over 30 years' experience in the global pharmaceutical sector, notably with GSK, ViiV Healthcare and currently as a Non-Executive Director of AIM-listed Allergy Therapeutics. Cheryl is an internationally recognised opinion leader in the development & commercialisation of medicines. Trained as a pharmacist, she has held numerous senior leadership positions in the UK, EU, US and Canada, with responsibilities including global commercial strategy, P&L, sales, marketing, operations and Board membership. Cheryl is passionate about bringing new therapies to the right patients who can benefit. Jordan Clark is Chief Data Officer at Diaceutics. Jordan spearheads Diaceutics' comprehensive data strategy, spanning acquisition engineering and data science, to deliver cutting-edge analytics to clients and laboratories. With over a decade of experience at Diaceutics, he has cultivated a profound understanding of the critical role real-world data plays in optimising precision medicine. Jordan's academic and professional credentials in biomedical and clinical sciences, coupled with his state licensure as a haematology scientist, underscore his expertise. Additionally, Jordan is renowned for proficiency testing, bioinformatics and biomarker testing, honed through his involvement with UK NEQAS. Major Estimate Revision • Sep 24
Consensus EPS estimates upgraded to UK£0.016 loss The consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -UK£0.021 to -UK£0.016 per share. Revenue forecast steady at UK£29.8m. Life Sciences industry in the United Kingdom expected to see average net income decline 24% next year. Consensus price target of UK£1.75 unchanged from last update. Share price rose 4.7% to UK£1.34 over the past week. Reported Earnings • Sep 23
First half 2024 earnings: EPS and revenues exceed analyst expectations First half 2024 results: UK£0.031 loss per share (further deteriorated from UK£0.018 loss in 1H 2023). Revenue: UK£12.3m (up 24% from 1H 2023). Net loss: UK£2.58m (loss widened 74% from 1H 2023). Revenue exceeded analyst estimates by 3.5%. Earnings per share (EPS) also surpassed analyst estimates by 5.3%. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance. Ankündigung • Sep 09
Diaceutics PLC to Report Q2, 2024 Results on Sep 17, 2024 Diaceutics PLC announced that they will report Q2, 2024 results on Sep 17, 2024 Ankündigung • Aug 27
Diaceutics PLC Launches Enhanced Rare-Disease Offering Diaceutics PLC announced a significant enhancement to its offering which has facilitated a new rare-disease contract win. Access to this new data will revolutionise the early identification of patients, a crucial growth area for pharma companies developing therapies for rare-diseases. Leveraging data utilisation, it will improve earlier patient diagnosis and ultimately, clinical outcomes. Driving this enhancement are 3 key developments within the Diaceutics business as follows: Onboarding of New Data Partners:A number of new rare-disease genomic lab data partners have joined the DXRX network. These partners specialise in genetic testing, including the recognised testing lab in the United States for genetically acquired rare diseases. Advanced Lab Labelling Natural Language Processing (NLP):Diaceutics has updated its advanced lab labelling NLP process to standardise and add value to the new data. This process enables complex labelling such as pathogenic vs Variants of Unknown Significance (VUS) variant calling which until now has proven challenging for the industry to identify. Access to Additional Industry Experts:The company now has a team of industry experts with deep rare-disease experience to support biopharma business opportunities and ensure clients derive maximum value from Diaceutics' deep-data offering. Despite medical and scientific advances, diagnosing rare diseases remains a significant challenge for biopharma companies. Many patients face years of multiple referrals, inconclusive test results and limited treatment benefits. Early diagnosis and quick interventions are crucial for patient survival and quality of life. A precision medicine approach can end these diagnostic odysseys and open opportunities for better clinical outcomes for patients in need. The strategic enhancements announced will enable Diaceutics to identify more patients earlier and in doing so, help pharma customers to better commercialise gene therapies for rare diseases. Leveraging these business enhancements, Diaceutics has already secured a new contract to provide a multi-product solution to support the commercialisation of a therapy in a rare autosomal-recessive disease. This initial contract win demonstrates Diaceutics' ability to meet the complex needs of this market. Ankündigung • Aug 19
Diaceutics PLC Announces Launch of PMx Diaceutics announced it has launched PMx, a suite of data-driven services built for the promotion and commercialisation of precision medicines and that it has reached agreement with a leading biotech to become its primary promotional partner for the launch of a breakthrough oncology precision medicine in the US using PMx. This partnership represents Diaceutics' seventh enterprise-wide engagement, and the first PMx primary promotional partnership deal whereby Diaceutics' fee structure is aligned with patient recruitment onto therapy. PMx unlocks new revenue streams for Diaceutics and shows the path to considerable increase in revenue per brand. Terms of the Agreement: Under the terms of the agreement, Diaceutics will leverage its DxRx platform, specifically its best-in-class genomic lab data, lab network, omni-channel, digital and peer to peer physician education to enable drug commercialisation. Diaceutics' partner will retain all rights to the license for the drug. This agreement is to deploy PMx through to the end of 2025 and is worth at least £2.4 million in service revenue to Diaceutics, with additional milestone fees estimated to be worth another £1.9 million payable during that period based on successful patient recruitment onto therapy. There is an expectation that the agreement will extend beyond 2025 should the initial phase be successful. Ankündigung • Jul 23
Diaceutics plc Announces Board Changes Diaceutics PLC announces the following changes to its board. Deborah Davis has informed the board after three and a half years' service as Non-Executive Chair of Diaceutics, of her intention to step down from the board effective 1 October 2024. Peter Keeling, a co-founder and Executive Director of Diaceutics will succeed Deborah as Non-Executive Chair effective 1 October 2024. Peter will also serve as a Non-Executive Director on the Remuneration and Audit & Risk Committees. Buy Or Sell Opportunity • Jul 09
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 27% to UK£1.32. The fair value is estimated to be UK£1.09, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 25% in a year. Earnings are forecast to decline by 29% in the next year. Major Estimate Revision • Jun 06
Consensus EPS estimates fall by 12% The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -UK£0.018 to -UK£0.021 per share. Revenue forecast unchanged at UK£29.5m. Life Sciences industry in the United Kingdom expected to see average net income growth of 31% next year. Consensus price target up from UK£1.68 to UK£1.72. Share price was steady at UK£1.32 over the past week. Price Target Changed • Jun 04
Price target increased by 8.1% to UK£1.72 Up from UK£1.59, the current price target is an average from 5 analysts. New target price is 30% above last closing price of UK£1.33. Stock is up 46% over the past year. Recent Insider Transactions • May 26
Independent Non-Executive Director recently bought UK£51k worth of stock On the 22nd of May, Graham Paterson bought around 40k shares on-market at roughly UK£1.29 per share. This transaction increased Graham's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought UK£105k more in shares than they have sold in the last 12 months. Reported Earnings • May 22
Full year 2023 earnings: Revenues in line with analyst expectations Full year 2023 results: Revenue: UK£23.7m (up 22% from FY 2022). Net loss: UK£1.75m (down 341% from profit in FY 2022). Revenue was in line with analyst estimates. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Ankündigung • Mar 21
Diaceutics PLC Launches Significant Upgrade to Its DXRX Platform Diaceutics PLC has launched a significant upgrade to its DXRX platform, including industry and technologically leading de-identification, generative AI (Diaceutics Large Lab Model, DLLM) and new comprehensive US data sets that include data on social determinants of health. Not only does the upgrade increase the power and efficiency of the platform, but also the applicability of Diaceutics' subscription services into new parts of the precision medicine lifecycle, expanding the Company's addressable market. This new functionality enables the DXRX platform to breakdown siloed datasets and provide greater depth and breadth of Diaceutics' longitudinal insight of the patient journey, at increased speed and scale. As a result of the upgrade, multiple stakeholders within the life sciences industry can now access a best in class, real world data set that is HIPAA compliant, at a pace that previously would not have been possible, helping to address healthcare inequalities and enable more patients to access appropriate therapies. New Risk • Mar 02
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: UK£79.0m (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (0.03% net profit margin). Market cap is less than US$100m (UK£79.0m market cap, or US$99.9m). New Risk • Oct 10
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: UK£80.1m (US$98.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (0.03% net profit margin). Market cap is less than US$100m (UK£80.1m market cap, or US$98.0m). Board Change • Oct 05
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Chair Llewelyn Davis was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Major Estimate Revision • Oct 03
Consensus EPS estimates upgraded to UK£0.017 loss The consensus outlook for fiscal year 2023 has been updated. 2023 losses forecast to reduce from -UK£0.019 to -UK£0.017 per share. Revenue forecast unchanged from UK£24.0m at last update. Life Sciences industry in the United Kingdom expected to see average net income growth of 5.5% next year. Consensus price target of UK£1.72 unchanged from last update. Share price was steady at UK£1.04 over the past week. Reported Earnings • Sep 28
First half 2023 earnings: EPS exceeds analyst expectations First half 2023 results: UK£0.018 loss per share (further deteriorated from UK£0.009 loss in 1H 2022). Revenue: UK£9.92m (up 32% from 1H 2022). Net loss: UK£1.49m (loss widened 94% from 1H 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 24%. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 60 percentage points per year, which is a significant difference in performance. New Risk • Sep 27
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.03% Last year net profit margin: 0.8% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company. Ankündigung • Sep 27
Diaceutics Announces Executive Changes Diaceutics announced the founder and chief executive of the company is stepping down after nearly two decades at the helm. Peter Keeling co-founded the company in 2005, growing it from a small consulting service provider to a listed company which employs 161 people across Europe and North America. He will step down as chief executive in January, with chief information officer Ryan Keeling becoming chief executive-designate with immediate effect. Ryan, who is Peter’s nephew, joined Diaceutics in 2006 and became a member of the board of directors following the company's listing on the AIM in 2019. Ankündigung • Sep 22
Diaceutics PLC Announces Executive Changes, Effective 1 October 2023 Diaceutics PLC announced the appointment of Graham Paterson as an independent Non-Executive Director of the company effective 1 October 2023. The Company also announced the retirement of Charles Hindson as a Non-Executive Director of Diaceutics PLC also effective 1 October 2023. Graham Paterson is a highly experienced business leader and Non-Executive Director. He is currently a Non-Executive Director of Invesco Perpetual UK Smaller Companies Investment Trust plc, Baillie Gifford US Growth Trust plc and Chairman of Mobeus Income and Growth 4 VCT plc.He has held senior executive roles in a number of companies including TopQ Software Ltd. and SL Capital Partners. Graham Paterson is a Chartered Accountant and a member of the Institute of Chartered Accountants of Scotland and holds an Honours degree in Economics and Management from the University of St. Andrews. On appointment, Graham Paterson will become Chair of the Audit and Remuneration Committees of Diaceutics PLC. Ankündigung • Aug 29
Diaceutics plc Launches Daily Alerts for Dxrx Platform Diaceutics PLC announced an important and innovative upgrade to its DXRX platformwhichsees the Company's DXRX Signal productnowproviding alerts on a daily basis. This ground-breaking innovation will provide Diaceutics' customers witheven more timely data to identifypatients who would benefit from their therapies and improve their commercial success. For patients, it means their chances of receiving the optimal therapy within the window of effectiveness is significantly improved. DXRX Signal utilizes real-world data collected from a diverse network of over ~500 labs, encompassing academic, community, and commercial facilities. This comprehensive data pool ensures supply chain reliability and encompasses both geographical and clinical diversity. For Diaceutics' customers, this translates into extensive coverage across a spectrum of medical conditions, including oncology, rare diseases, auto-immune disorders, cardiovascular and infectious diseases. DXRX Signal has identified over 46,000 patients so far in 2023 for its biopharma clients. Building upon the foundation of DXRX Signal, Diaceutics has introduced this pivotal enhancement. These alerts, now available on a daily basis, empower Diaceutics' customers with even timelier insights as they deploy products to pinpoint patients and elevate their commercial success. This innovation equips healthcare professionals with crucial data on a daily basis, and within days of a positive test result. With increased timely access to diagnostic information, physicians can be engaged precisely during the treatment decision window, ensuring the most effective drugs or therapies are offered promptly to patients. Ankündigung • Jul 25
Diaceutics PLC to Report First Half, 2023 Results on Sep 26, 2023 Diaceutics PLC announced that they will report first half, 2023 results on Sep 26, 2023 Reported Earnings • Apr 19
Full year 2022 earnings released: EPS: UK£0.009 (vs UK£0.007 in FY 2021) Full year 2022 results: EPS: UK£0.009 (up from UK£0.007 in FY 2021). Revenue: UK£19.5m (up 40% from FY 2021). Net income: UK£724.0k (up 29% from FY 2021). Profit margin: 3.7% (down from 4.0% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Reported Earnings • Sep 27
First half 2022 earnings released: UK£0.009 loss per share (vs UK£0.004 loss in 1H 2021) First half 2022 results: UK£0.009 loss per share (further deteriorated from UK£0.004 loss in 1H 2021). Revenue: UK£7.53m (up 26% from 1H 2021). Net loss: UK£767.0k (loss widened 129% from 1H 2021). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. CFO & Director Nick Roberts was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Apr 10
Executive Officer recently sold UK£198k worth of stock On the 6th of April, Philip White sold around 200k shares on-market at roughly UK£0.99 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of UK£397k more than they bought in the last 12 months. Reported Earnings • Sep 16
First half 2021 earnings released: UK£0.004 loss per share (vs UK£0.015 profit in 1H 2020) The company reported a soft first half result with weaker earnings and weaker control over costs, although revenues improved. First half 2021 results: Revenue: UK£5.97m (up 13% from 1H 2020). Net loss: UK£335.0k (down 131% from profit in 1H 2020). Recent Insider Transactions • May 07
CFO & Executive Director recently sold UK£246k worth of stock On the 4th of May, Philip White sold around 200k shares on-market at roughly UK£1.23 per share. This was the largest sale by an insider in the last 3 months. This was Philip's only on-market trade for the last 12 months. Reported Earnings • Mar 16
Full year 2020 earnings released The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: UK£12.7m (down 5.6% from FY 2019). Net income: UK£263.0k (down 34% from FY 2019). Profit margin: 2.1% (down from 3.0% in FY 2019). Is New 90 Day High Low • Mar 16
New 90-day low: UK£1.12 The company is down 5.0% from a price of UK£1.19 on 16 December 2020. Underperformed the British market, which is up 5.0% over the last 90 days. Lagged the Life Sciences industry, which is up 19% over the same period. Is New 90 Day High Low • Jan 05
New 90-day high: UK£1.42 The company is up 20% from its price of UK£1.19 on 07 October 2020. The British market is up 11% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Life Sciences industry, which is up 31% over the same period. Valuation Update With 7 Day Price Move • Dec 29
Investor sentiment improved over the past week After last week's 16% share price gain to UK£1.34, the stock is trading at a trailing P/E ratio of 29.3x, up from the previous P/E ratio of 25.3x. This compares to an average P/E of 51x in the Life Sciences industry in the United Kingdom. Total returns to shareholders over the past year are 31%.